Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R ... MarketWatch NEW YORK, Nov 08, 2013 (BUSINESS WIRE) -- Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE(R) (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE ... |
